PER-025-18尚未招募未知
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATORCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO6867461 IN PATIENTS WITH DIABETIC MACULAR EDEMA (YOSEMITE)
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 13
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients must meet the following general inclusion criteria for study entry:
- •Willingness and the ability to provide signed informed consent
- •Additionally, at U.S. sites, patients must provide Health Insurance Portability and Accountability Act authorization, and in other countries, as applicable according to national laws.
- •Age 18 years
- •Documented diagnosis of diabetes mellitus (Type 1 or Type 2), as defined by the American Diabetes Association or per WHO criteria and
- •–Current regular use of insulin for the treatment of diabetes
- •–Current regular use of oral anti-hyperglycemic agents for the treatment of diabetes
- •HbA1c of 10% within 2 months prior to the Day 1 visit date
- •Ability and willingness to undertake all scheduled visits and assessments
- •For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the treatment period and for at least 3 months after the final dose of study treatment
排除标准
- •Currently untreated diabetes mellitus or previously untreated patients who initiated oral anti diabetic medication or insulin within 3 months prior to Day 1
- •History of allergy or hypersensitivity to active drug aflibercept and any of its excipients, fluorescein, or any study treatmentrelated mandatory ingredients.
- •History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the RO6867461 or to aflibercept injections, study treatment procedure, dilating drops, or any of the anesthetic and antimicrobial drops used by a patient during the study
- •Active cancer within the past 12 months except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of 6 and a stable prostate-specific antigen for 12 months
- •Systemic treatment for suspected or active systemic infection
- •Renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis within 6 months prior to Day 1 or anticipated to require hemodialysis or peritoneal dialysis at any time during the study
- •History of other disease, other non-diabetic metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of the RO6867461 or aflibercept or that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications in the opinion of the investigator
- •Uncontrolled blood pressure (defined as systolic 180 mmHg and/or diastolic 100 mmHg while a patient is at rest)
- •Cerebral vascular accident or myocardial infarction within 6 months prior to Day 1
- •Pregnancy or breastfeeding, or intention to become pregnant during the study
- •Participation in an investigational trial that involves treatment with any drug or device (with the exception of vitamins and minerals) within 3 months prior to Day 1
- •Administration of systemic pro-angiogenic treatments, such as VEGF based therapies for the peripheral or coronary ischemia (e.g., limb ischemia or myocardial infarction) within 3 months or 5 half-lives prior to Day 1
- •Inability to comply with study or follow-up procedures
研究者
相似试验
进行中（未招募）
1 期
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (Study #1)EUCTR2014-000107-27-DEF. Hoffmann-La Roche Ltd936
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Central Retinal or Hemiretinal Vein OcclusioEUCTR2020-000441-13-FRF.Hoffmann La-Roche Ltd680
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Branch Retinal Vein OcclusioEUCTR2020-000440-63-HUF.Hoffmann La-Roche Ltd520
进行中（未招募）
1 期
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (Study #2)EUCTR2014-000106-35-HUF. Hoffmann-La Roche Ltd936
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration (Lucerne)EUCTR2018-004042-42-DKF.Hoffmann La-Roche Ltd658